Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: Pharmacokinetic properties, safety, and immunologic and virologic effects

Pediatrics

Volumn 97, Issue 6 I, 1996, Pages 886-890

  Kline, Mark W ^a   Fletcher, Courtney V ^b   Federici, Marianne E ^c   Harris, Alice T ^a   Evans, Kim D ^a   Rutkiewicz, Victoria L ^a   Shearer, William T ^a   Dunkle, Lisa M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

child; didanosine; HIV infection; infant; stavudine

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PILOT PROJECTS; RNA, VIRAL; STAVUDINE;

EID: 0029943432     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pavia AT, Gathe J, BMS-019 Study Group Investigators, et al. Clinical efficacy of stavudine (d4T, Zerit) compared to zidovudine (ZDV, Retrovir) in ZDV-pretreated HIV positive patients. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; 1995:235. Abstract 1169
2. 3 after at least 6 months ZDV treatment. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; 1995:235. Abstract 1170
3. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 1995;96:247-252
4. Executive Summary: ACTG 152. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group, Bethesda, MD, February 28, 1996
5. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993;119:786-793
6. Browne MJ, Mayer KH, Chafee SBD, et al. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21-29
7. Yarchoan R, Mitsuya H, Fluda JM, et al. The National Cancer Institute phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis. 1990;12(suppl 5):S522-S533
8. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics. 1994;94:724-731
9. Sommadossi J-P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. J Infect Dis. 1995;171(suppl 2):S88-S92
10. Merrill DP, Moonis M, Chou T-C, Hirsch MS. Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996;173:355-364
11. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43(RR-12):1-10
12. D'Argenio DZ, Schumitzky A, Wolf W. Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Computer Methods Programs Biomed. 1988;27:47-54
13. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis. 1992;165:99-104
14. Ross Growth and Development Program. Incremental Growth Charts. Columbus, OH: Ross Laboratories; 1990
15. Seifert RD, Stewart MB, Sramek JJ, et al. Pharmacokinetics of coadministered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol. 1994;38:405-410
16. Lin P-F, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy J Infect Dis. 1994;170:1157-1164
17. Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses. 1995;11:353-361
18. 3. Presented at the Second National Conference on Human Retroviruses; Washington, DC; 1995. Abstract LB31